Interview with Hoon Han, President, Histostem
After spending a large part of your career as a university professor, what drove you to create your own company, Histostem, in 2000? In 1993, I actually established a bone…
Address: Seongnam jungwongu beltway 210 (sangdaewondong) 101
Tel: (031)-732-1555
Web: http://www.seoulcord.co.kr/index1.asp
Histostem is a stem cell provider, specializing in the MLPCs (Multi-Lineage Progenitor Cells) research, the treatment of disease and injury, and the banking of stem cells. Stem cells are the body’s “master” cells because they give rise to all other tissues, organs, and systems in the body. The stemcells’ ability to differentiate, or change, into other types of cells in the body, is a fairly new discovery that holds tremendous promise for treating and curing some of the most common diseases such as heart diseases, cancers, stroke, paralysis, liver cirrhosis, Buerger’s and Alzheimer’s diseases. What’s more, this treatment is not years away. Histostem is already using hematopoietic stemcells taken from UCB to treat blood diseases such as various kinds of leukemia, multiple sclerosis, amyotrophic lateral sclerosis, etc. Histostem also succeeded in extracting non-hematopoietic multipotent stem cells from UCB in their most pure state and perfected in multiplying and cultivating those stemcells. Histostem is the world’s first runner in applying our stem cell therapy to human patients, and currently using our stem cells to treat with great success such illnesses as Buerger’s disease, Type II diabetes, liver cirrhosis, paralysis after spinal cord injury, osteoporosis, chronic renal failure, and Alzheimer’s disease, to name a few. Finally, in order to achieve the most effective donor matching of cord blood to patient, our research technicians are busy typing the human leukocyte antigens (HLA) in our biogenetics laboratory.
Stem cell provider, specializing in the MLPCs (Multi-Lineage Progenitor Cells) research, the treatment of disease and injury, and the banking of stem cells.
After spending a large part of your career as a university professor, what drove you to create your own company, Histostem, in 2000? In 1993, I actually established a bone…
Bae Byoung-Jun, director general of the Bureau of Health Industry at Korea’s Ministry of Health and Welfare, outlines the history and structure of the Korean healthcare system and highlights the…
LSK Global PS CEO Young-Jack Lee discusses the influence of global CROs on the quality of Korean research, and outlines his own strategy for competing in the marketplace and growth…
Sanofi’s Korean affiliate is the fifth largest recipient of clinical trial investments after the United States, France, Germany and the United Kingdom. Kay Bae, general manager, discusses the benefits of…
Song In-Keum, chairman of the Korean Medical Devices Industry Association (KMDIA), discusses current opportunities offered by Korea’s growing medtech industry. What have been your priorities since you became the…
The Korean Institute of Toxicology (KIT) is a government-funded research institute that evaluates the safety of medicine, bio-related products and chemicals. PharmaBoardroom talks to Lee Sang-Joon, President of KIT about…
Korea possesses enormous potential to become an exporter of futuristic health systems in the near future, and has already started the process. Kim Han-Joong, chairman of the strategy committee at…
The Korea Drug Research Association (KDRA) was founded in 1986 to represent local pharmaceutical companies in their mission for global drug development. Kang-Choo Lee, president of KDRA, discusses the current…
The president of Astellas Korea offers his perspectives on Korea as a base for primary and clinical research, and the company’s recent partnerships in the country. You became president…
The head researcher at P&K Skin Research Center discusses the potential of South Korea as a clinical trial hub, and the company’s current expansion plans. What differentiates P&K Skin…
Don Hyun, president of MSD Korea, shares his vision to bring Korean pharmaceutical companies to the global stage and to bring a locally produced drug to blockbuster status in the…
The director of the Hanyang University Hospital for Rheumatic Diseases (HUHRD), discusses Korea’s leading role in developing biosimilars as well as the hospital’s efforts to curb chronic diseases. As…
The Korea National Enterprise for Clinical Trials (KoNECT) was established in 2007 by the Korean government to meet the increasing demand for local clinical trials and strengthen the country’s clinical research…
See our Cookie Privacy Policy Here
